IMMIX BIOPHARMA, INC.
Loading stock data...
Key Financial Metrics (TTM | FY 2024)
-
Revenue
$-23.56M
Net Income
-0.77
EPS (Diluted)
$-24.39M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
$-24.05M
Returns & Efficiency
Return on Assets (ROA)
-117.34%
Return on Equity (ROE)
-285.09%
Gross Profit
-
Operating Income
$-24.05M
Financial Health
Total Assets
$20.08M
Total Debt
-
Debt to Equity
1.43x
Current Ratio
1.53
Debt Analysis
Debt to EBITDA
-
Debt to Free Cash Flow
-
Cash & Equivalents
-
Net Debt
-
Capital Returns
Return on Invested Capital (ROIC)
-
Invested Capital
-
Stockholders Equity
-
Revenue Growth
-
Market Valuation
Market Cap
-
P/E Ratio
-
Price to Book
-
EPS (Diluted)
$-0.77
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Insider Transactions
Neutral
Open Market Buys: -
Open Market Sales: -
Option Exercise & Sale: -
Net: -
Loading...
Loading insider transactions...
My Notes & Files
Personal Notes
Attached Files
Loading...
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address |
11400 WEST OLYMPIC BLVD.
SUITE 200 LOS ANGELES, CA 90064 |
| Phone | (888) 958-1084 |
| Incorporated | DE, US |
| EIN | 454869378 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 31.93M |
| Stockholders' Equity | $8.26M |
| Cash & Equivalents | $15.95M |
Recent Filings
View All
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-02-17
Local
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-02-17
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-11-07
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-08-08
Local
10-K/A
Amended Annual Report
Amendment to previously filed annual report
Filed: 2025-05-19
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-05-08
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2025-04-30
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2025-03-25
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-11-12
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-08-12
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2024-05-09
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2024-04-29
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2024-03-29
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2023-11-13
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2023-08-11
Local
Financial Statistics
Valuation
Market Cap
-
P/E Ratio (TTM)
-
Price to Book
-
EV/Revenue
-
EV/EBITDA
-
Profitability
Gross Margin
-
Operating Margin
-
Net Margin
-
ROE
-285.1%
ROA
-117.3%
Leverage & Liquidity
Debt to Equity
1.43
Current Ratio
1.53
Total Debt
-
Total Assets
$20.08M
Stockholders' Equity
$8.26M
Income Statement (FY 2024)
Revenue
-
Gross Profit
-
Operating Income
$-24.05M
Net Income
$-23.56M
EPS (Diluted)
$-0.77
Cash Flow (FY 2024)
Free Cash Flow
$-24.39M
Cash & Equivalents
$15.95M
Revenue Growth
-
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...